ArticleEuropean heart journal2023
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe.
Article in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 168 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multimodal Vascular Phenotyping and Target-Organ Damage Using Vascular Imaging, Glyco-Oxidative Biomarkers, and Photoplethysmography in Adults at Increased Cardiovascular Risk: The GlycOxiTOD Observational Registry
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study.
CArdiovascular Risk Assessment Via Multimodal Data Analysis Enabling Personalised Prevention Strategies Targeting MEnopausaL Women - Observational Study
Who cites it
168 citing papers in PubMed, 3 syntheses or guidelines pooled it, 268 citations in OpenAlex.
- Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline.BMJ (Clinical research ed.) · 2025Guideline
- Overcoming Missing Data: Accurately Predicting Cardiovascular Risk in Type 2 Diabetes, A Systematic Review.Journal of diabetes · 2025Pooled it
- [Cardiovascular preventive recommendations. PAPPS 2024 thematic updates].Atencion primaria · 2024Guideline
- APOSCREEN-1 - a prospective, single-arm clinical trial for the implementation of a pharmacy-based screening for cardiovascular-kidney-metabolic risk factors in Schleswig-Holstein.BMC nephrology · 2026Trial
- A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Cardiovascular risk equations in type 1 diabetes: from generic models to personalized prediction.Annals of medicine · 2026Review
- Incidence and independent risk factors for heart failure in a population-based cohort of 19,892 individuals with newly diagnosed diabetes.Diabetologia · 2026Article
- The liver in diabetes: current state and future perspectives.Diabetologia · 2026Review
- Type 2 diabetes subtypes for precision medicine: methodological challenges and alternative prediction-based approaches.Diabetologia · 2026Review
- Integrated Cardio-Renal-Metabolic Risk Profiling in Patients with Type 2 Diabetes: A Machine Learning-Assisted Cross-Sectional Analysis.Journal of clinical medicine · 2026Article
- Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.European heart journal · 2026Article
- A CVD Classification Model for Individuals With Obesity: Multi-Ethnic Validation Based on Multiple Metabolic Indicators.Obesity (Silver Spring, Md.) · 2026Article
- Blood-Based DNA Methylation Models Improve Short-term Cardiovascular Risk Stratification in Individuals With Type 2 Diabetes.Diabetes care · 2026Article
- Major ECG abnormalities and risk of incident cardiovascular disease in people with HIV compared to people without HIV.AIDS (London, England) · 2026Article
- Association of the Pan-Immune-Inflammation Value-to-Albumin Ratio as a Novel Cardiovascular Disease Predictor in Type 2 Diabetes: A Prospective Cohort Study.Biomedicines · 2026Article
- Article
- Six-Month Cardiometabolic and Vascular Trajectories After COVID-19 Hospitalization: Exploratory Associations with Recorded Dietary and Omega-3 Management.Journal of clinical medicine · 2026Article
- Real-World Attainment of Guideline-Recommended Lipid Targets in Patients with High and Very High Cardiovascular Risk: A Prospective 12-Month Observational Cohort Study.Journal of clinical medicine · 2026Article
- Beyond SCORE2: Rethinking Cardiovascular Risk Assessment in a Very-High-Risk European Setting-A Narrative Review and Proposal of the ROMA-CV Algorithm for Romania.Journal of clinical medicine · 2026Review
- Quantifying the Predictive Power of Social Determinants of Health in Cardiovascular Disease and Type 2 Diabetes Progression Using XGBoost: Retrospective Cohort Study.JMIR medical informatics · 2026Article
108 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
Abstract
aimsTo develop and validate a recalibrated prediction model (SCORE2-Diabetes) to estimate the 10-year risk of cardiovascular disease (CVD) in individuals with type 2 diabetes in Europe. METHODS AND
resultsSCORE2-Diabetes was developed by extending SCORE2 algorithms using individual-participant data from four large-scale datasets comprising 229 460 participants (43 706 CVD events) with type 2 diabetes and without previous CVD. Sex-specific competing risk-adjusted models were used including conventional risk factors (i.e. age, smoking, systolic blood pressure, total, and HDL-cholesterol), as well as diabetes-related variables (i.e. age at diabetes diagnosis, glycated haemoglobin [HbA1c] and creatinine-based estimated glomerular filtration rate [eGFR]). Models were recalibrated to CVD incidence in four European risk regions. External validation included 217 036 further individuals (38 602 CVD events), and showed good discrimination, and improvement over SCORE2 (C-index change from 0.009 to 0.031). Regional calibration was satisfactory. SCORE2-Diabetes risk predictions varied several-fold, depending on individuals' levels of diabetes-related factors. For example, in the moderate-risk region, the estimated 10-year CVD risk was 11% for a 60-year-old man, non-smoker, with type 2 diabetes, average conventional risk factors, HbA1c of 50 mmol/mol, eGFR of 90 mL/min/1.73 m2, and age at diabetes diagnosis of 60 years. By contrast, the estimated risk was 17% in a similar man, with HbA1c of 70 mmol/mol, eGFR of 60 mL/min/1.73 m2, and age at diabetes diagnosis of 50 years. For a woman with the same characteristics, the risk was 8% and 13%, respectively.
conclusionSCORE2-Diabetes, a new algorithm developed, calibrated, and validated to predict 10-year risk of CVD in individuals with type 2 diabetes, enhances identification of individuals at higher risk of developing CVD across Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.